Clinical research on treatment of advanced primary liver cancer with combination of thymosin [alpha]1 and arsenic trioxide

Clinical research on treatment of advanced primary liver cancer with combination of thymosin [alpha]1 and arsenic trioxide

A total of 59 patients with advanced PLC who were admitted to Jiangyan Hospital of Traditional Chinese Medicine from July 2011 to July 2014 were divided into two groups: control group and combination therapy group. The two groups were given symptomatic and supportive treatment to protect the liver....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Linchuang gandanbing zazhi 2015-04, Vol.31 (4), p.564-568
Hauptverfasser: GAO, Chengguang, CHEN, Rixia
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 568
container_issue 4
container_start_page 564
container_title Linchuang gandanbing zazhi
container_volume 31
creator GAO, Chengguang
CHEN, Rixia
description A total of 59 patients with advanced PLC who were admitted to Jiangyan Hospital of Traditional Chinese Medicine from July 2011 to July 2014 were divided into two groups: control group and combination therapy group. The two groups were given symptomatic and supportive treatment to protect the liver. In addition, 29 cases in the control group were treated with arsenic trioxide, while 30 cases in the combination therapy group were administrated with thymosin al combined with arsenic trioxide. The levels of alpha fetal protein, carcinoembryonic antigen, carbohydrate antigen 199, and gamma glutamyl transpeptidase decreased in both groups, and the combination therapy group had significantly higher decreases in these indices than the control group (P < 0.05). The combination therapy group had significantly increased percentages of CD3 super(+) and CD4 super(+) T cells and CD4 super(+)/CD8 super(+) ratio (P < 0.05) and a significantly reduced percentage of CD8 super(+) T cells (P < 0.01) after treatment.
doi_str_mv 10.3969/j.issn.1001-5256.2015.04.021
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1712564936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1712564936</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_17125649363</originalsourceid><addsrcrecordid>eNqVjjtPAzEQhF2AlPD4D1tQ0MTY9wpXRyB-AB1C0eLb6Dby4_A6gfDrOSRETzXSaL6ZUerGGl33XX-31ywStTXGrtqq7XRlbKtNo01lz9Tyz1-oC5G9MY3t7-ul-tp4juzQQyYhzG6EFKFkwhIoFkg7wOGI0dEAU-aA-QSej5TB_ZgZPriM4FJ444iFZ3YmyngKSTjCC_ppxFcLGAfALDRPzeWcPnmgK3W-Qy90_auX6vbx4XnztJpyej-QlG1gceQ9RkoH2dq1nf83fd3V_4h-AwFAWuQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1712564936</pqid></control><display><type>article</type><title>Clinical research on treatment of advanced primary liver cancer with combination of thymosin [alpha]1 and arsenic trioxide</title><source>EZB Electronic Journals Library</source><creator>GAO, Chengguang ; CHEN, Rixia</creator><creatorcontrib>GAO, Chengguang ; CHEN, Rixia</creatorcontrib><description>A total of 59 patients with advanced PLC who were admitted to Jiangyan Hospital of Traditional Chinese Medicine from July 2011 to July 2014 were divided into two groups: control group and combination therapy group. The two groups were given symptomatic and supportive treatment to protect the liver. In addition, 29 cases in the control group were treated with arsenic trioxide, while 30 cases in the combination therapy group were administrated with thymosin al combined with arsenic trioxide. The levels of alpha fetal protein, carcinoembryonic antigen, carbohydrate antigen 199, and gamma glutamyl transpeptidase decreased in both groups, and the combination therapy group had significantly higher decreases in these indices than the control group (P &lt; 0.05). The combination therapy group had significantly increased percentages of CD3 super(+) and CD4 super(+) T cells and CD4 super(+)/CD8 super(+) ratio (P &lt; 0.05) and a significantly reduced percentage of CD8 super(+) T cells (P &lt; 0.01) after treatment.</description><identifier>ISSN: 1001-5256</identifier><identifier>DOI: 10.3969/j.issn.1001-5256.2015.04.021</identifier><language>eng</language><ispartof>Linchuang gandanbing zazhi, 2015-04, Vol.31 (4), p.564-568</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>GAO, Chengguang</creatorcontrib><creatorcontrib>CHEN, Rixia</creatorcontrib><title>Clinical research on treatment of advanced primary liver cancer with combination of thymosin [alpha]1 and arsenic trioxide</title><title>Linchuang gandanbing zazhi</title><description>A total of 59 patients with advanced PLC who were admitted to Jiangyan Hospital of Traditional Chinese Medicine from July 2011 to July 2014 were divided into two groups: control group and combination therapy group. The two groups were given symptomatic and supportive treatment to protect the liver. In addition, 29 cases in the control group were treated with arsenic trioxide, while 30 cases in the combination therapy group were administrated with thymosin al combined with arsenic trioxide. The levels of alpha fetal protein, carcinoembryonic antigen, carbohydrate antigen 199, and gamma glutamyl transpeptidase decreased in both groups, and the combination therapy group had significantly higher decreases in these indices than the control group (P &lt; 0.05). The combination therapy group had significantly increased percentages of CD3 super(+) and CD4 super(+) T cells and CD4 super(+)/CD8 super(+) ratio (P &lt; 0.05) and a significantly reduced percentage of CD8 super(+) T cells (P &lt; 0.01) after treatment.</description><issn>1001-5256</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqVjjtPAzEQhF2AlPD4D1tQ0MTY9wpXRyB-AB1C0eLb6Dby4_A6gfDrOSRETzXSaL6ZUerGGl33XX-31ywStTXGrtqq7XRlbKtNo01lz9Tyz1-oC5G9MY3t7-ul-tp4juzQQyYhzG6EFKFkwhIoFkg7wOGI0dEAU-aA-QSej5TB_ZgZPriM4FJ444iFZ3YmyngKSTjCC_ppxFcLGAfALDRPzeWcPnmgK3W-Qy90_auX6vbx4XnztJpyej-QlG1gceQ9RkoH2dq1nf83fd3V_4h-AwFAWuQ</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>GAO, Chengguang</creator><creator>CHEN, Rixia</creator><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20150401</creationdate><title>Clinical research on treatment of advanced primary liver cancer with combination of thymosin [alpha]1 and arsenic trioxide</title><author>GAO, Chengguang ; CHEN, Rixia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_17125649363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GAO, Chengguang</creatorcontrib><creatorcontrib>CHEN, Rixia</creatorcontrib><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Linchuang gandanbing zazhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GAO, Chengguang</au><au>CHEN, Rixia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical research on treatment of advanced primary liver cancer with combination of thymosin [alpha]1 and arsenic trioxide</atitle><jtitle>Linchuang gandanbing zazhi</jtitle><date>2015-04-01</date><risdate>2015</risdate><volume>31</volume><issue>4</issue><spage>564</spage><epage>568</epage><pages>564-568</pages><issn>1001-5256</issn><abstract>A total of 59 patients with advanced PLC who were admitted to Jiangyan Hospital of Traditional Chinese Medicine from July 2011 to July 2014 were divided into two groups: control group and combination therapy group. The two groups were given symptomatic and supportive treatment to protect the liver. In addition, 29 cases in the control group were treated with arsenic trioxide, while 30 cases in the combination therapy group were administrated with thymosin al combined with arsenic trioxide. The levels of alpha fetal protein, carcinoembryonic antigen, carbohydrate antigen 199, and gamma glutamyl transpeptidase decreased in both groups, and the combination therapy group had significantly higher decreases in these indices than the control group (P &lt; 0.05). The combination therapy group had significantly increased percentages of CD3 super(+) and CD4 super(+) T cells and CD4 super(+)/CD8 super(+) ratio (P &lt; 0.05) and a significantly reduced percentage of CD8 super(+) T cells (P &lt; 0.01) after treatment.</abstract><doi>10.3969/j.issn.1001-5256.2015.04.021</doi></addata></record>
fulltext fulltext
identifier ISSN: 1001-5256
ispartof Linchuang gandanbing zazhi, 2015-04, Vol.31 (4), p.564-568
issn 1001-5256
language eng
recordid cdi_proquest_miscellaneous_1712564936
source EZB Electronic Journals Library
title Clinical research on treatment of advanced primary liver cancer with combination of thymosin [alpha]1 and arsenic trioxide
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A03%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20research%20on%20treatment%20of%20advanced%20primary%20liver%20cancer%20with%20combination%20of%20thymosin%20%5Balpha%5D1%20and%20arsenic%20trioxide&rft.jtitle=Linchuang%20gandanbing%20zazhi&rft.au=GAO,%20Chengguang&rft.date=2015-04-01&rft.volume=31&rft.issue=4&rft.spage=564&rft.epage=568&rft.pages=564-568&rft.issn=1001-5256&rft_id=info:doi/10.3969/j.issn.1001-5256.2015.04.021&rft_dat=%3Cproquest%3E1712564936%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1712564936&rft_id=info:pmid/&rfr_iscdi=true